Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-LUNG)
Sponsor: Addario Lung Cancer Medical Institute
Terminated
Recruitment futility
Other terminated trials from Addario Lung Cancer Medical Institute
See all terminations from Addario Lung Cancer Medical Institute
Other NSCLC Stage IV trials with similar outcome
A observational or N/A phase clinical study on NSCLC Stage IV and NSCLC, Stage IIIC, this trial is terminated or withdrawn. The trial is conducted by Addario Lung Cancer Medical Institute and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Mar 2024 — Jul 2024 [monthly]
Terminated
Status: Suspended → Terminated
-
Feb 2023 — Mar 2024 [monthly]
Suspended
Status: Recruiting → Suspended
-
Feb 2022 — Feb 2023 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Dec 2021 — Feb 2022 [monthly]
Recruiting
-
Mar 2021 — Dec 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Addario Lung Cancer Medical Institute
- Biodesix, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .